203 related articles for article (PubMed ID: 20520573)
1. A correlation between latanoprost-induced conjunctival hyperemia and intraocular pressure-lowering effect.
Kobayashi H; Kobayashi K
J Glaucoma; 2011 Jan; 20(1):3-6. PubMed ID: 20520573
[TBL] [Abstract][Full Text] [Related]
2. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
[TBL] [Abstract][Full Text] [Related]
3. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
[TBL] [Abstract][Full Text] [Related]
4. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study.
Lopes JF; Hubatsch DA; Amaris P
BMC Ophthalmol; 2015 Nov; 15():166. PubMed ID: 26563363
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study.
Uusitalo H; Pillunat LE; Ropo A;
Acta Ophthalmol; 2010 Feb; 88(1):12-9. PubMed ID: 20420586
[TBL] [Abstract][Full Text] [Related]
6. Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial.
Hatanaka M; Reis A; Sano ME; Susanna R
J Glaucoma; 2010; 19(5):331-5. PubMed ID: 19730119
[TBL] [Abstract][Full Text] [Related]
7. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients.
Konstas AG; Katsimbris JM; Lallos N; Boukaras GP; Jenkins JN; Stewart WC
Ophthalmology; 2005 Feb; 112(2):262-6. PubMed ID: 15691561
[TBL] [Abstract][Full Text] [Related]
8. A Prospective, randomized, investigator-masked evaluation of the monocular trial in ocular hypertension or open-angle glaucoma.
Realini TD
Ophthalmology; 2009 Jul; 116(7):1237-42. PubMed ID: 19576495
[TBL] [Abstract][Full Text] [Related]
9. Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost.
Stewart WC; Kolker AE; Stewart JA; Leech J; Jackson AL
Am J Ophthalmol; 2003 Mar; 135(3):314-20. PubMed ID: 12614748
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
Orzalesi N; Rossetti L; Bottoli A; Fogagnolo P
Ophthalmology; 2006 Feb; 113(2):239-46. PubMed ID: 16458092
[TBL] [Abstract][Full Text] [Related]
11. Effects of latanoprost 50 micrograms/ml on Chinese patients with primary open-angle glaucoma and ocular hypertension.
Liu CJ; Chou JC; Hsu WM; Liu JH
Zhonghua Yi Xue Za Zhi (Taipei); 1999 Oct; 62(10):703-9. PubMed ID: 10533300
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of bimatoprost as replacement for latanoprost in patients with glaucoma or ocular hypertension: a uniocular switch study.
Casson RJ; Liu L; Graham SL; Morgan WH; Grigg JR; Galanopoulos A; Crawford A; House PH
J Glaucoma; 2009; 18(8):582-8. PubMed ID: 19826386
[TBL] [Abstract][Full Text] [Related]
13. Effect on diurnal intraocular pressure of the fixed combination of latanoprost 0.005% and timolol 0.5% administered in the evening in glaucoma.
Polo V; Larrosa JM; Ferreras A; Borque E; Pablo LE; Honrubia FM
Ann Ophthalmol (Skokie); 2008; 40(3-4):157-62. PubMed ID: 19230353
[TBL] [Abstract][Full Text] [Related]
14. The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients.
Costagliola C; Parmeggiani F; Antinozzi PP; Caccavale A; Cotticelli L; Sebastiani A
Exp Eye Res; 2005 Nov; 81(5):610-5. PubMed ID: 15949795
[TBL] [Abstract][Full Text] [Related]
15. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
Stewart WC; Konstas AG; Nelson LA; Kruft B
Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
[TBL] [Abstract][Full Text] [Related]
17. A model-based meta-analysis of the effect of latanoprost chronotherapy on the circadian intraocular pressure of patients with glaucoma or ocular hypertension.
Luu KT; Raber SR; Nickens DJ; Vicini P
Clin Pharmacol Ther; 2010 Apr; 87(4):421-5. PubMed ID: 20164834
[TBL] [Abstract][Full Text] [Related]
18. Additive ocular hypotensive effect of latanoprost and acetazolamide. A short-term study in patients with elevated intraocular pressure.
Rulo AH; Greve EL; Hoyng PF
Ophthalmology; 1997 Sep; 104(9):1503-7. PubMed ID: 9307648
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the 24-hour intraocular pressure-lowering effects of latanoprost and dorzolamide/timolol fixed combination after 2 and 6 months of treatment.
Konstas AG; Kozobolis VP; Tsironi S; Makridaki I; Efremova R; Stewart WC
Ophthalmology; 2008 Jan; 115(1):99-103. PubMed ID: 18166407
[TBL] [Abstract][Full Text] [Related]
20. Ocular hypotensive effect of PhXA41 in patients with ocular hypertension or primary open-angle glaucoma.
Hotehama Y; Mishima HK; Kitazawa Y; Masuda K
Jpn J Ophthalmol; 1993; 37(3):270-4. PubMed ID: 8295364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
